Table 3.

Outcomes at 1 year by presentation and treatment

	Acute coronary syndromes			Chronic coronary syndromes			Pinteraction
	Supreme DES, n = 441	DP-EES, n = 232	P	Supreme DES, n = 645	DP-EES, n = 310	P
Primary outcome
Target lesion failure	6.6% (28)	6.0% (14)	.89	4.5% (29)	4.3% (13)	.83	.96
Secondary outcomes
Major adverse coronary events	8.9% (38)	7.8% (18)	.72	6.4% (41)	6.8% (21)	.81	.67
Target vessel failure	7.3% (31)	7.8% (18)	.72	5.5% (35)	5.2% (16)	.86	.71
Any death	0.7% (3)	1.8% (4)	.21	0.5% (3)	1.3% (4)	.16	.93
Cardiac death	0.5% (2)	1.4% (3)	.43	0.2% (1)	0.3% (1)	.59	.86
Any myocardial infarction	5.6% (24)	5.2% (13)	.90	4.2% (27)	3.9% (12)	.82	.95
Periprocedural	1.6% (7)	4.7% (11)	.02	3.1% (20)	2.9% (9)	.87	.06
Spontaneous	4.0% (17)	1.0% (2)	.03	1.2% (8)	1.3% (4)	.95	.11
Any revascularization	6.4% (28)	3.6% (8)	.11	4.2% (27)	4.3% (13)	1.00	.26
Target lesion revascularization	2.9% (12)	0.9% (2)	.10	2.2% (14)	1.1% (3)	.19	.72
Clinically driven	2.9% (12)	0.9% (2)	.10	1.9% (12)	1.1% (3)	.30	.61
Target vessel revascularization	4.5% (19)	3.1% (7)	.40	3.3% (21)	2.9% (9)	.77	.67
Clinically driven	4.5% (20)	3.1% (7)	.40	3.0% (19)	2.9% (9)	.97	.55
Nontarget vessel revascularization	3.0% (13)	1.8% (4)	.33	1.6% (10)	2.1% (6)	.66	.37
Any bleeding (BARC definition)	3.5% (15)	5.7% (13)	.17	2.5% (16)	1.3% (4)	.23	.08
BARC 3 or 5	3.3% (14)	1.3% (3)	.14	1.6% (10)	0.7% (2)	.24	.97
Definite stent thrombosis	0.0%	0.4% (1)	.17	0.9% (6)	0.3% (1)	.30	.99
Early (0-30 d)	0.0%	0.4% (1)	.17	0.8% (5)	0.3% (1)	.41	.99
Late (31-365 d)	0.0%	0.0%	—	0.2% (1)	0.0%	.49	>.99
Definite/probable stent thrombosis	0.2% (1)	0.4% (1)	.64	1.1% (7)	0.3% (1)	.23	.30
Early (0-30 d)	0.2% (1)	0.4% (1)	.64	0.9% (6)	0.3% (1)	.30	.34
Late (31-360 d)	0.0%	0.0%	—	0.2% (1)	0.0%	.49	>.99

Values are given as % (n).

BARC, Bleeding Academic Research Consortium; DES, drug-eluting stent; DP-EES, durable polymer everolimus-eluting stent.